1875 — TOT Biopharm International Co Income Statement
0.000.00%
Last trade - 00:00
- HK$1.65bn
- HK$1.65bn
- CNY780.63m
- 17
- 23
- 71
- 26
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 45.3 | 22.5 | 76.3 | 442 | 781 |
Cost of Revenue | |||||
Gross Profit | 34 | 15.5 | 27.5 | 371 | 574 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 315 | 311 | 336 | 481 | 814 |
Operating Profit | -270 | -289 | -260 | -39.1 | -33.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -299 | -288 | -261 | -50 | -37.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -299 | -288 | -261 | -50 | -37.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -299 | -288 | -261 | -49.9 | -37.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -299 | -288 | -261 | -49.9 | -37.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.761 | -0.507 | -0.446 | -0.073 | -0.039 |